BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Conor Medsystems, Inc. Purchases Assets Of Phytogen Life Sciences


11/22/2005 1:32:23 PM

MENLO PARK, Calif., Nov. 22 /PRNewswire-FirstCall/ -- Conor Medsystems, Inc. today announced that it has purchased substantially all of the assets of Phytogen Life Sciences Inc., including its inventory of finished paclitaxel, for approximately $3.8 million.

In July 2005, Phytogen filed for bankruptcy. Prior to its bankruptcy filing, Phytogen supplied Conor with finished paclitaxel pursuant to a supply agreement. Under the terms of the supply agreement, Conor was obligated to pay Phytogen a royalty based on the sales of Conor's CoStar(TM) cobalt chromium paclitaxel-eluting stent. As a result of this transaction, Conor's supply agreement with Phytogen and its royalty obligation under the supply agreement have been terminated.

Conor expects to account for the transaction as an acquisition of assets. Conor anticipates selling most of the assets acquired in the transaction, except for an amount of finished paclitaxel that Conor believes will be sufficient to meet its investigational and commercial needs for many years.

About Conor Medsystems

Conor Medsystems, Inc. develops innovative controlled vascular drug delivery technologies and has initially focused on the development of drug- eluting stents to treat coronary artery disease. For further information about Conor and controlled vascular delivery, visit www.conormed.com.

CoStar(TM) is not available for sale in the U.S. CoStar is an investigational device limited by federal law to investigational use.

Forward-looking statements

This press release contains certain forward-looking statements that involve risks and uncertainties, including the statement related to the accounting treatment of the acquisition, the statement related to the company's intent to sell most of the assets acquired in the transaction, and the statement related to the company's belief that it will retain a sufficient amount of paclitaxel. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. All forward-looking statements and other information included in this press release are based on information available to the company as of the date hereof, and the company assumes no obligation to update any such forward-looking statements or information. The company's actual results and the timing of events could differ materially from those described in the company's forward-looking statements as a result of these risks and uncertainties, which include (1) the risk that the company may be unable to sell any of the assets acquired in the transaction and (2) the risks discussed in detail under the heading "Risk Factors" in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2005, filed with the SEC on November 14, 2005, including, (A) risks related to the uncertain, lengthy and expensive clinical development and regulatory process, (B) risks related to the loss of the company's single source suppliers, and (C) risks related to the company or its suppliers not achieving or complying with required regulatory approvals for manufacturing operations.

Conor Medsystems, Inc.

CONTACT: Investor inquiries, Michael Boennighausen, Chief FinancialOfficer of Conor Medsystems, Inc., +1-650-614-4100; or Media inquiries,Karen L. Bergman of BCC Partners, +1-650-575-1509, for Conor Medsystems,Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES